Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland

This multicenter, comparative cohort study evaluated the long-term use of fermented European mistletoe extract (Iscador) as an adjuvant therapy in patients with intermediate- to high-risk malignant melanoma (UICC/AJCC stage II-III). The treatment group, receiving subcutaneous mistletoe 2-3 times per week, showed improved tumor-related survival, better disease-free survival, and fewer brain